Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup

Posted:
8
November 2011

Richmond Pharmacology enhances its established GE MUSE platform with theState-of-the-art Mortara 12-lead telemetry setupEnhancing our well tested GE MUSE platform, Richmond Pharmacology today added the state-of-the-art Mortara 12-lead telemetry setup providing the most comprehensive TQT measurement platform available.Key features include:

  • 12-lead Telemetry Monitoring

With the Mortara X12+  and T12S  transmitters, the Surveyor  Telemetry Central System enables continuous 12-lead monitoring and trending for thorough evaluation of ECG intervals, ST segment change, and arrhythmias using VERITAS  ECG algorithms.

  • 12-lead ECG On-Demand

Continuous 12-lead monitoring enables diagnostic 12-lead ECG acquisition on-demand without any additional device or patient hookup.  12-lead ECGs with VERITAS measurements and interpretation can be printed and exported to an E-Scribe� data management system either manually or automatically.This is an alternative to our established GE GETEMED 12-lead Holter platform.At Richmond Pharmacology we are so confident that we can deliver a successful TQT study we ensure a fixed price guarantee. Furthermore our confidence in our experience means that should we fail to show Thorough QT assay sensitivity we will repeat your study at no cost to you.Contact a member of our Business Development team now to discuss your prospective QT study requirements.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more